our chairman and chief executive officer since June 2021, is a life sciences industry veteran with more than 21 years of experience advising, investing and transacting in the healthcare sector. Mr. Siegel is the
founder and chief executive officer of JBS Healthcare Ventures, a firm focused on developing cost effective
solutions to improve healthcare outcomes since its formation in 2017. Previously, he was a partner and
healthcare sector head at Kingdon Capital Management, a New York City-based investment management
company, from 2011 until 2017. Prior to joining Kingdon, Mr. Siegel was a healthcare portfolio manager at SAC
Capital Advisors from 2005 until 2011; an associate director of pharmaceutical and specialty pharmaceutical
research at Bear, Stearns & Co.; a pharmaceuticals research associate at Dresdner Kleinwort Wasserstein; and a
consultant in the Life Sciences Division of Computer Sciences Corporation. Mr. Siegel has worked as a research
associate at the Novartis Center for Immunobiology at Harvard Medical School where he published and
presented at conferences in the field of Xenotransplantation and as a research assistant at Tufts University School
of Medicine. He is also a director at Jaguar Health, Inc. since 2018 and Sol-Gel Technologies Ltd since
September 2018, both Nasdaq listed companies, and has served on the board of advisors of Vitalis LLC, a private
pharmaceutical company, since March 2019. Previously he served on the board of directors of Lumara Health, a
private pharmaceutical company from September 2013 through October 2013 and was a board observer from
November 2013 to November 2014. Mr. Siegel received a BS in Psychology from Tufts University in 1995 and
an MBA from Columbia Business School in 1999.